Drugs / BILR 355
BILR 355
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02253940 | Oct → Dec 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02253927 | May → Aug 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BILR 355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02253940 ↗ |
| Known as | BILR 355 (SDS) | “A secondary objective was to explore the effect of food on the pharmacokinetics of BILR 355 (SDS)” NCT02253927 ↗ |
| Known as | BILR 355 BS | “The primary objective was to explore the relative bioavailability of increasing doses of BILR 355 BS, as a sodium dodecyl sulfate-containing solid formulation (SDS), in...” NCT02253927 ↗ |
| Modality | Small molecule | — CHEMBL1630842 ↗ |
| Route | Oral | “225 Mg-450 mg) Oral Administration” NCT02253927 ↗ |